Cancer touches our lives in many ways.

Stock exchange releases

• 9/20/2024 213,285 Orion Corporation A shares converted into B shares
• 9/11/2024 Inside information: Orion upgrades full-year outlook for 2024
• 8/14/2024 44,767 Orion Corporation A shares converted into B shares
• 8/8/2024 Orion Group Half-Year Financial Report January–June 2024

All releases 

Press releases

• 9/30/2024 Orion’s near-term climate targets approved by the Science Based Targets initiative
• 9/26/2024 Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
• 9/25/2024 Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
• 9/16/2024 Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

All releases 